Pure Bioscience (PURE)
OTHER OTC:PURE
Want to see PURE full AI Analyst Report?
Top Page
Pure Bioscience
(OTC:PURE)
Select Model
Select Model
Rating:45Neutral
Price Target:
$0.07
▲(32.00% Upside)
Action:Reiterated
Date:05/06/26
The score is driven primarily by weak financial performance—ongoing losses, recurring cash burn, and negative equity—creating elevated funding and balance-sheet risk. Technical indicators are neutral-to-soft and do not offset the fundamentals. Recent financing and governance approvals provide some liquidity and flexibility, but also highlight reliance on external capital.
Positive Factors
Proprietary SDC technology and IP
Pure's core technology—patented silver-dihydrogen citrate (SDC)—is a durable competitive asset that underpins product differentiation across food safety, healthcare, and industrial sanitation. Ownership of IP supports licensing, private-label deals and protects margins as the company scales commercial adoption.
Negative Factors
Negative shareholder equity and weak capitalization
Persistent negative equity materially weakens financial flexibility and increases refinancing and insolvency risk. With equity deficits across multiple years, the company faces constrained borrowing capacity and greater vulnerability to shocks, raising long-term funding and continuity concerns.
Read all positive and negative factors
Positive Factors
Negative Factors
Proprietary SDC technology and IP
Pure's core technology—patented silver-dihydrogen citrate (SDC)—is a durable competitive asset that underpins product differentiation across food safety, healthcare, and industrial sanitation. Ownership of IP supports licensing, private-label deals and protects margins as the company scales commercial adoption.
Read all positive factors
Pure Bioscience (PURE) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$8.09M
Dividend YieldN/A
Average Volume (3M)53.72K
Price to Earnings (P/E)―
Beta (1Y)-0.80
Revenue Growth29.27%
EPS Growth30.32%
CountryUS
Employees11
SectorConsumer Defensive
Sector Strength42
IndustryHousehold & Personal Products
Share Statistics
EPS (TTM)-0.02
Shares Outstanding111,886,475
10 Day Avg. Volume24,352
30 Day Avg. Volume53,720
Financial Highlights & Ratios
PEG Ratio0.15
Price to Book (P/B)>-0.01
Price to Sales (P/S)0.00456
P/FCF Ratio>-0.01
Enterprise Value/Market Cap1.84
Enterprise Value/Revenue6.19
Enterprise Value/Gross Profit0.01
Enterprise Value/Ebitda-8.30
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Pure Bioscience Business Overview & Revenue Model
Company Description
PURE Bioscience, Inc. develops and commercializes antimicrobial products that provide solutions to the health and environmental challenges of pathogen and hygienic control in the United States and internationally. The company manufactures and dist...
How the Company Makes Money
Pure Bioscience makes money primarily by selling products that use its silver-dihydrogen citrate (SDC) antimicrobial technology and by monetizing associated intellectual property. Key revenue streams include: (1) Product sales: revenue from the sa...
Pure Bioscience Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
9
Very Negative
Cash Flow
14
Very Negative
| Breakdown | TTM | Jul 2025 | Jul 2024 | Jul 2023 | Jul 2022 | Jul 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.41M | 2.20B | 1.96M | 1.88M | 1.85M | 3.93M |
| Gross Profit | 1.30B | 1.30B | 1.15M | 971.00K | 1.00M | 2.08M |
| EBITDA | -1.80M | -2.10M | -3.05M | -3.83M | -3.27M | -2.14M |
| Net Income | -2.16M | -2.40M | -3.35M | -3.96M | -3.50M | -2.32M |
Balance Sheet | ||||||
| Total Assets | 788.00K | 1.06B | 818.00K | 1.82M | 4.48M | 4.30M |
| Cash, Cash Equivalents and Short-Term Investments | 198.00K | 334.00M | 349.00K | 1.09M | 3.39M | 2.39M |
| Total Debt | 6.14M | 5.24B | 2.95M | 1.02M | 0.00 | 239.00K |
| Total Liabilities | 7.06M | 6.17B | 3.68M | 1.55M | 575.00K | 970.00K |
| Stockholders Equity | -6.27M | -5.12B | -2.86M | 272.00K | 3.91M | 3.33M |
Cash Flow | ||||||
| Free Cash Flow | -1.82M | -2.02B | -2.53M | -3.31M | -2.50M | -1.69M |
| Operating Cash Flow | -1.82M | -2.02B | -2.53M | -3.28M | -2.42M | -1.17M |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | -33.00K | -81.00K | -521.00K |
| Financing Cash Flow | 1.82M | 2.00B | 1.78M | 1.01M | 3.50M | 239.00K |
Pure Bioscience Technical Analysis
Positive
0.05
Price Trends
0.07
Negative
0.06
Positive
0.07
Positive
Market Momentum
>-0.01
Negative
50.45
Neutral
79.17
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PURE, the sentiment is Positive. The current price of 0.05 is below the 20-day moving average (MA) of 0.07, below the 50-day MA of 0.07, and below the 200-day MA of 0.07, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 50.45 is Neutral, neither overbought nor oversold. The STOCH value of 79.17 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for PURE.
Pure Bioscience Risk Analysis
Pure Bioscience disclosed 39 risk factors in its most recent earnings report. Pure Bioscience reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Pure Bioscience Peers Comparison
UnderperformOutperform
Sector (62)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
81 Outperform | $32.94M | 9.40 | 21.40% | 9.81% | -4.13% | -18.10% | |
62 Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% | |
56 Neutral | $2.74M | -0.07 | 3.65% | ― | -10.67% | ― | |
47 Neutral | $52.11M | -12.70 | -106.32% | ― | -13.98% | 64.53% | |
47 Neutral | $8.25M | ― | 16.79% | ― | ― | ― | |
45 Neutral | $8.09M | -1.66 | 127.81% | ― | 29.27% | 30.32% | |
42 Neutral | $8.43M | 2.93 | -19.54% | ― | -7.51% | -6001.27% |
* Consumer Defensive Sector Average
PURE
Pure Bioscience
0.07
-0.01
-12.20%
MTEX
Mannatech
4.37
-5.15
-54.10%
UG
United-Guardian
7.17
-0.48
-6.23%
TANH
Tantech Holdings
0.42
-1.63
-79.51%
GROV
Grove Collaborative Holdings
1.24
-0.19
-13.29%
TKLF
Yoshitsu Co. Ltd. Sponsored ADR
1.95
-1.95
-50.00%
Pure Bioscience Corporate Events
Business Operations and StrategyPrivate Placements and Financing
Pure Bioscience Raises $1 Million in Private Placement
Positive
May 5, 2026
On April 30, 2026, PURE Bioscience, Inc. completed a $1.0 million private placement to accredited investors, issuing 18,131,096 common shares at $0.0553 per share under a Securities Purchase Agreement. Board members Tom Y. Lee and Ivan Chen partic...
Business Operations and StrategyExecutive/Board ChangesShareholder Meetings
Pure Bioscience Shareholders Back Governance, Expand Stock Authorization
Positive
Feb 20, 2026
Pure Bioscience, Inc. held its Annual Meeting of Stockholders on February 17, 2026, with approximately 66% of outstanding shares represented, and shareholders elected all seven director nominees with overwhelming majorities to serve until the next...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.